A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders

@article{Norman1995ARA,
  title={A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders},
  author={Trevor R. Norman and Graham D. Burrows},
  journal={Drug Safety},
  year={1995},
  volume={12},
  pages={46-54}
}
SummaryMoclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders. Comparative studies have shown that the drug is more effective than placebo and as effective as other antidepressants. In terms of efficacy, moclobemide offers no more benefits than do existing agents. On the other hand, moclobemide is better tolerated than tricyclic antidepressants and, unlike irreversible… Expand
Moclobemide in social phobia: a controlled dose-response trial.
TLDR
In this dose-response trial, moclobemide did not demonstrate efficacy at 12 weeks, and some other controlled studies have found moclOBemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Expand
Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo.
TLDR
Strong evidence is provided that lamotrigine did not modulate oral tyramine-induced hypertension in rats or 5-hydroxytryptophan-induced head shaking in mice, providing strong evidence that the drug does not perturb monoamine metabolism in vivo. Expand
Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.
TLDR
Moclobemide overdose in combination with a serotonergic agent (even in normal therapeutic doses) can cause severe serotonin toxicity, and the elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses. Expand
MAO-inhibitors in Parkinson's Disease
TLDR
In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential. Expand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
TLDR
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
Designing a new generation of antidepressant drugs
  • R. Pinder
  • Medicine, Psychology
  • Acta psychiatrica Scandinavica. Supplementum
  • 1997
TLDR
Mirtazapine, the prototype noradrenergic and specific serotonergic antidepressant (NaSSA), specifically enhances 5‐HT, neurotransmission and blocks 5-HT2 and 5‐ HT3 receptors, and in contrast to venlafaxine lacks SSRI‐like and adverse cardiovascular side effects. Expand
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
TLDR
Treatment of depression frequently involves the use of drugs such as monoamine oxidase inhibitors, tricyclic antidepressants (TCAs), and, more recently, selective serotonin reuptake inhibitors (SSRIs). Expand
ANTIDEPRESSANTS: CLINICAL ASPECTS
Several new agents for the treatment of depression have been introduced in recent years. While there are certain advantages for these agents over existing drugs, their efficacy and speed of onset ofExpand
Depression in vascular pathologies: the neurologist’s point of view
TLDR
The significance of depression in clinical daily practice, its pathophysiology as a determinant in vascular events, and its real importance in, before, and after many CVD events are examined. Expand
Plasma and human milk concentrations of moclobemide in nursing mothers
TLDR
Based on the milk to plasma ratio, the infants were exposed to <1% of the maternal dose, and this exposure did not appear to have any adverse effects on the infants' developmental milestones as judged by clinical observation. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
RIMA — A new concept in the treatment of depression with moclobemide
TLDR
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent that is devoid of any clinically significant tyramine interaction, thus making dietary restrictions during therapy unnecessary. Expand
An update of recent moclobemide interaction data
  • J. Dingemanse
  • Chemistry, Medicine
  • International clinical psychopharmacology
  • 1993
TLDR
In combination with therapeutic doses of either fluvoxamine or fluoxetine, moclobemide did not provide any indication of a serotoninergic syndrome, so that no wash-out period is needed when switching from a selective serotonin re-uptake inhibitor to moclOBemide or vice versa. Expand
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
TLDR
When the tolerability of moclobemide, as judged by reported and observed adverse events, is compared to that of placebo, it appears that only nausea is reported significantly more frequently with moclOBemide than with placebo; in particular the incidence of anticholinergic side effects was low with mclobemides and was significantly higher with the TCAs. Expand
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
TLDR
In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients and results have shown that the active drug was markedly superior to placebo. Expand
Clinical overview on moclobemide
  • J. Tiller
  • Medicine, Psychology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1993
1. Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression,Expand
The role of moclobemide in endogenous depression: a survey of recent data
  • B. Woggon
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 1993
TLDR
The antidepressant efficacy of both moclobemide and reference drugs was more pronounced in endogenous than in non-endogenous depression, whatever the severity. Expand
Serotonin syndrome caused by a moclobemide-clomipramine interaction.
TLDR
A 7T year old woman with depression and Parkinson's disease has a case of serotonin syndrome induced by the reversible monoamine oxidase A inhibitor moclobemide and the serotonin reuptake inhibitor clomipramine, and fulfilled the diagnostic criteria for the serotonin syndrome suggested by Sternbach. Expand
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
TLDR
The neurochemical profile of moclobemide indicates clearly that this nonhydrazine nonhepatotoxic MAO-A inhibitor represents a novel and safe drug for treatment of affective disorders. Expand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
TLDR
The reversible MAO-A inhibitors moclobemide and brofaromine, due to their well-documented safety characteristics, to their lack of anticholinergic-effects and to their good tolerability, will provide innovative tools for clarifying the role of MAO -A inhibitors in the treatment of endogenous and atypical depressive states. Expand
...
1
2
3
...